Have you ever wondered why extraordinary scientific breakthroughs quietly vanish every year? A novel molecule demonstrates breathtaking target selectivity in vitro, cures disease models in mice, and generates glowing peer-reviewed papers in high-impact journals. Yet, three years later, the spinout behind it has quietly liquidated, the lab stands empty, and the intellectual property sits gathering dust in a university tech transfer archive.
The hard truth of the life sciences sector is that biology does not care about your capital runway, and financial markets do not care about the elegance of your mechanism of action. Founders and researchers frequently fall into the “scientific trap.” They believe that if the science is compelling enough, capital, regulatory approval, and commercial adoption will automatically follow. But science is merely the ticket to the game; it is not the strategy that wins it. Building a sustainable biotech company requires a fundamentally different set of tools: translating technical mechanisms into risk-adjusted financial models, capital allocation strategies, and clear commercial positioning.
To bridge the gap between scientific excellence and commercial viability, founders, researchers, and investors must realign around three operational realities:
- Capital Alignment and Runway Architecture: A scientific breakthrough is only as viable as the capital structure supporting it. Therapeutics must be funded to reach distinct, value-accretive clinical milestones—not just arbitrary calendar dates. Running out of money 80% of the way to a Phase 2a data readout yields the same commercial outcome as having no data at all.
- Early Reimbursement and Market Realism: Discovering a target is a biological challenge; securing reimbursement is an economic one. Designing a drug without early input on target product profiles (TPPs), payer requirements, and standard-of-care competition often results in scientifically successful drugs that no health system is willing to buy.
- Governance Beyond Technical Consensus: Academic science thrives on peer review, exploration, and exhaustive consensus. Corporate biotech demands speed, capital prioritization, and relentless focus. A board made up entirely of scientific advisors will rarely make the hard, cold decision to kill a lagging lead asset to save the company’s cash runway.
Great biotech companies are not built by scientists who happen to run businesses, nor by financiers who treat medicine like abstract software code. They are built at the intersection of both, where scientific rigor meets disciplined financial execution, just as DUAL FLUENCY by David H. Crean, Ph.D., highlights why scientific excellence alone is not enough to build successful life sciences companies. The book introduces the concept of Dual Fluency, the ability for leaders to operate effectively in both the language of science and the language of capital, enabling them to translate discoveries into investment opportunities, strategic partnerships, and sustainable organizations.
Drawing from decades of experience in life sciences transactions, advisory work, and leadership, Crean explains how companies succeed or fail at three critical translation points: Data to Capital, where scientific evidence becomes an investment thesis; Discovery to Deal, where innovation becomes strategic value; and Bench to Boardroom, where scientific insight and financial judgment guide leadership decisions.
Through practical frameworks, real world examples, and leadership lessons, the book provides founders, executives, investors, and board members with the tools needed to navigate uncertainty, allocate resources wisely, and move transformative therapies from discovery to patients.